Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Atif J Khan; Par S Mehta; Thomas W Zusag; Philip D Bonomi; L Penfield Faber; Susan Shott; Ross A Abrams

doi:10.1016/j.radonc.2006.09.006

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Radiother Oncol. 2006 Nov;81(2):163-7. doi: 10.1016/j.radonc.2006.09.006. Epub 2006 Oct 16.

Authors

Atif J Khan¹, Par S Mehta, Thomas W Zusag, Philip D Bonomi, L Penfield Faber, Susan Shott, Ross A Abrams

Affiliation

¹ Department of Radiation Oncology, Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA.

PMID: 17050016
DOI: 10.1016/j.radonc.2006.09.006

Abstract

We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.

MeSH terms

Adult
Aged
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / secondary
Carcinoma, Non-Small-Cell Lung / therapy*
Combined Modality Therapy / methods*
Disease-Free Survival
Female
Humans
Lung Neoplasms / mortality
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Male
Middle Aged
Neoplasm Metastasis
Treatment Outcome